Regeneron's Expense Growth Weighs on Operating Income

Date : 05/07/2019 @ 12:13PM
Source : Dow Jones News
Stock : Regeneron Pharmaceuticals, Inc. (REGN)
Quote : 298.11  -4.98 (-1.64%) @ 12:59AM

Regeneron's Expense Growth Weighs on Operating Income

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Historical Stock Chart

3 Months : From Apr 2019 to Jul 2019

Click Here for more Regeneron Pharmaceuticals, Inc. Charts.
   By Allison Prang 
 

Earnings at Regeneron Pharmaceuticals Inc. (REGN) declined in the first quarter as expenses grew by 30%, climbing faster than revenue.

Regeneron reported $461.1 million in profit, which was down 3.5% from the comparable quarter a year prior. Earnings were $3.99 a share, down from $4.16 a share.

The company's adjusted earnings were $4.45 a share, down from $4.67 a share. Analysts polled by Refinitiv were expecting $5.46 a share.

Revenue rose 13% to $1.71 billion. Analysts were expecting $1.76 billion. Expenses rose 30%.

 

Write to Allison Prang at allison.prang@wsj.com

 

(END) Dow Jones Newswires

May 07, 2019 06:58 ET (10:58 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest REGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.